Hypocalcemia in a Dialysis Patient Treated With Deferasirox for Iron Overload

American Journal of Kidney Diseases

Volumn 52, Issue 3, 2008, Pages 587-590

  Yusuf, Bushra ^a   McPhedran, Peter ^a   Brewster, Ursula C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chelation; end stage renal disease; Exjade; ferritin; Hypocalcemia; iron overload

Indexed keywords

DEFERASIROX; IRON CHELATING AGENT;

ADULT; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPOCALCEMIA; IRON CHELATION; IRON OVERLOAD; KIDNEY DISEASE; KIDNEY FAILURE; LONG TERM CARE; PERITONEAL DIALYSIS; RECURRENT DISEASE; SICKLE CELL NEPHROPATHY; SYMPTOMATOLOGY;

ADULT; ANEMIA, SICKLE CELL; BENZOIC ACIDS; BLOOD TRANSFUSION; ERYTHROPOIETIN; FEMALE; HUMANS; HYPERTENSION; HYPOCALCEMIA; IRON CHELATING AGENTS; IRON OVERLOAD; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; TRIAZOLES;

EID: 49749144119     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.03.034     Document Type: Article

References (20)

1. Borgna-Pignatti C., Rugolotto S., De Stefano P., et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89 (2004) 1187-1193
2. Schrier S.L., and Angelucci E. New strategies in the treatment of the thalassemias. Annu Rev Med 56 (2005) 157-171
3. Olivieri N.F., and Brittenham G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 89 (1997) 739-761
4. Arboretti R., Tognoni G., Alberti D., and Italian Colaborative Group on Thalassemia. Pharmacosurveillance and quality of care of thalassemic patients. A large scale epidemiological survey. Eur J Clin Pharmacol 56 (2001) 915-922
5. Cohen A. Management of iron overload in the pediatric patient. Hematol Oncol Clin North Am 1 (1987) 521-544
6. Kingswood C., Banks R.A., Bunker T., Harrison P., and Mackenzie C. Fracture osteomalacia, CAPD, and aluminium. Lancet 1 8314-5 (1983) 70-71
7. Payton C.D., Junor B.J., and Fell G.S. Successful treatment of aluminium encephalopathy by intraperitoneal desferrioxamine. Lancet 1 8386 (1984) 1132-1133
8. Boelaert J.R., van Roost G.F., Vergauwe P.L., Verbanck J.J., de Vroey C., and Segaert M.F. The role of desferrioxamine in dialysis-associated mucormycosis: Report of three cases and review of the literature. Clin Nephrol 29 (1988) 261-266
9. de Locht M., Boelaert J.R., and Schneider Y.J. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of rhizopus microsporus. Biochem Pharmacol 47 (1994) 1843-1850
10. Neufeld E.J. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: New data, new questions. Blood 107 (2006) 3436-3441
11. Cappellini M.D., Cohen A., Piga A., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107 (2006) 3455-3462
12. Nisbet-Brown E., Olivieri N.F., Giardina P.J., et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 361 (2003) 1597-1602
13. Guggenbuhl P., Deugnier Y., Boisdet J.F., et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 16 (2005) 1809-1814
14. Voskaridou E., and Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 127 (2004) 127-139
15. Mandalunis P., and Ubios A. Experimental renal failure and iron overload: A histomorphometric study in rat tibia. Toxicol Pathol 33 (2005) 398-403
16. Matsushima S., Torii M., Ozaki K., and Narama I. Iron lactate-induced osteomalacia in association with osteoblast dynamics. Toxicol Pathol 31 (2003) 646-654
17. Van de Vyver F.L., Visser W.J., D'Haese P.C., and De Broe M.E. Iron overload and bone disease in chronic dialysis patients. Nephrol Dial Transplant 5 (1990) 781-787
18. Andress D.L., Nebeker H.G., Ott S.M., et al. Bone histologic response to deferoxamine in aluminum-related bone disease. Kidney Int 31 (1987) 1344-1350
19. Brown D.J., Dawborn J.K., Ham K.N., and Xipell J.M. Treatment of dialysis osteomalacia with desferrioxamine. Lancet 2 8294 (1982) 343-345
20. Klein G.L., Snodgrass W.R., Griffin M.P., Miller N.L., and Alfrey A.C. Hypocalcemia complicating deferoxamine therapy in an infant with parenteral nutrition-associated aluminum overload: Evidence for a role of aluminum in the bone disease of infants. J Pediatr Gastroenterol Nutr 9 (1989) 400-403